Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy

Shalaby, Asem; Mahmoud, Heba A; Sayed, Shayma G; Al Hashmi, Khalid; Al-Sinawi, Shadia; Al Badi, Suad; Al Rashdi, Afrah; Al Husaini, Samya; Al Badi, Hajer; Saad El-Din, Somaia Ahmed

doi:10.31557/APJCP.2024.25.6.2193

Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy

Document Type : Research Articles

Authors

¹ Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

² Department of Pathology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

³ Department of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

⁴ Department of Hematology and Medical Oncology, Armed Forces Hospital, Muscat, Oman.

⁵ Department of Histopathology, Armed Forces Hospital, Muscat, Oman.

10.31557/APJCP.2024.25.6.2193

Abstract

The alterations of EGFR and HER2/neu as growth factor receptors and the cytoplasmic signal transduction proteins of RAS/RAF/MAP kinases including its end effector molecule (ERK) are important in the carcinogenesis of many tumors. The activation of these protooncogenes in prostate cancer is still under investigation. The aim of this work was to study EGFR, HER2- neu, inactive (non-phosphorylated) and active (phosphorylated) ERK expression in prostatic adenocarcinomas in correlation to the clinical and pathological parameters. Methods: Immunohistochemistry- using tissue microarrays- for EGFR, HER2/neu, non-phosphorylated, and phosphor-ERK, was performed on tissues from 166 patients- with primary prostatic adenocarcinoma with no prior treatment-. The results of different markers expression were correlated with the clinical and pathological parameters and were analyzed statistically. Results: The prostatic tissue showed EGFR, HER2 neu, phosphorylated and non-phosphorylated ERK expression in 8.4%, 1.4%, 78.2%, and 83.4% respectively whether low (patchy) or high expression (diffuse). There were no significant correlations found between patient characteristics and expression of the tested markers. The negative immune reactivity for non-phosphorylated ERK and EGFR- was significantly correlated with high tumor stage (p values 0.03 and 0.01, respectively). Conclusion: EGFR and HER2/neu may play a limited role in prostatic adenocarcinoma as they showed positive expression in a limited number of the examined tissues specifically HER2neu. The expression of non-phosphorylated ERK (mostly weak to moderate) and phosphorylated ERK (mostly moderate to strong)- was appreciated in most cases. Thus, we suggest that anti-EGFR drugs may have a limited role in the treatment of castrate-resistant prostate cancer, but anti-MEK/ERK drugs may have more promising role as a target therapy. It is recommended to perform further molecular testing to elucidate the exact mechanism and significance of these markers.

Keywords